d[Cha4]-AVP is a vasopressin analog featuring a D-cyclohexylalanine substitution that alters steric geometry and folding. The modification supports exploration of conformational constraints in cyclic peptides. Hydrophobic elements influence interaction surfaces. Researchers apply it in structure–activity mapping of AVP derivatives.
CAT No: R0966
CAS No:500170-27-4
Synonyms/Alias:d[Cha4]AVP;500170-27-4;(Deamino-Cys1,beta-cyclohexyl-Ala4,Arg8)-Vasopressin;CHEMBL265858;d(Cha4)AVP;(deamino-Cys1,Cha4)AVP;[deamino-Cys1,Cha4]AVP;(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide;(1-deamino-4-cyclohexylalanine)AVP;[1-Deamino-4-Cyclohexylalanine]AVP;BDBM50205312;AKOS024457445;FD109768;(Deamino-Cys1,b-cyclohexyl-Ala4,Arg8)-Vasopressin trifluoroacetate salt;
1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
4. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.